Open-source automated insulin delivery
Open-source automated insulin delivery has been studied in 1 paper since 2026: 1 observational study in people; 1 in the past year. The newest paper, Jun 5, 2026: “Beyond Insulin Alone: One-Year CGM Outcomes of Adjunctive Incretin-Based and SGLT2 Inhibitors Therapy in Type 1 Diabetes Using Open-Source Automated Insulin Delivery Systems”.
1 paper studies it2 findingsUpdated
See all 1 papers on open-source automated insulin delivery
At a glance
The findings reach people, from one lab or study. 1 lab.
“Average Time in Range (TIR) rose from 63% at baseline to 73% at 12 months.”
None of its findings points the other way.
- 1 lab
- Humans1
What did studies of open-source automated insulin delivery find?
2Studies of open-source automated insulin delivery measured 2 outcomes: time below range and time in range.
Time below range
no changein humans1
1 study
Time below range
no changein humans1
Open-source automated insulin delivery was not clearly linked with time below range in humans with adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors (averaged 2%).
Humanswith adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors12 monthsn = 357
Time in range
upin humans1
1 study
Time in range
upin humans1
Open-source automated insulin delivery is linked with higher time in range in humans with adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors (63% to 73% at 12 months).
Humanswith adjunctive semaglutide, tirzepatide or SGLT-2 inhibitors12 monthsn = 357